BW 20507
Alternative Names: BW-20507; Hepatitis B siRNALatest Information Update: 04 Mar 2024
At a glance
- Originator Argo Biopharma
- Class Antivirals; Small interfering RNA
- Mechanism of Action Hepatitis B surface antigen expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Hepatitis B
Most Recent Events
- 20 Feb 2024 BW 20507 is available for licensing as of 20 Feb 2024. https://www.argobiopharma.com/partnering/index.html (Argo Biopharma pipeline, February 2024)
- 02 Aug 2023 Phase-I/II clinical trials in Hepatitis B (In adults) in Thailand (SC), Australia (SC), Hong Kong (SC) (ACTRN12623000708651)
- 01 Jun 2023 Argo Biopharma has patent protection related to "Composition and method for inhibiting expression of hepatitis b virus protein" worldwide